Basic Information
| RNALocate ID: | RLID:01001271 |
| RNA Symbol: | hsa-miR-17-5p |
| Localization: | Mitochondrion |
RNA Information
| RNA Name: | hsa-miR-17 |
| RNA ID: | miRBase:MIMAT0000070 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 21637849 |
| Tissue/Cell Line: | Skeletal muscle myoblasts |
| Method: | ISH|qRT-PCR |
| Description: | List of microRNA significantly detected in the mitochondrial mRNA at three increasing mtRNA inputs (1, 5 and 35 uL). Table S3 List of microRNA significantly detected (Cp<35) in the mitochondrial mRNA at the two highest mtRNA inputs (5 and 35 uL). Data are collected from Table 4 and S3. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01001267 | Cytoplasm | Nasopharyngeal carcinoma cells | 20498841 |
| RLID:01001268 | Cytoplasm | Neural progenitor cells | 21363885 |
| RLID:01001269 | Cytoplasm | Cell line (HeLa) | 21695135 |
| RLID:01001270 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001272 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
| RLID:01001273 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001274 | Nucleolus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001275 | Nucleus | Nasopharyngeal carcinoma cells | 20498841 |
| RLID:01001276 | Nucleus | Colon adenocarcinoma cells | 20864815 |
| RLID:11000686 | Exosome | Serum | 29143228 |
| RLID:11000687 | Exosome | Peripheral blood mononuclear cells | 19002258 |
| RLID:11000688 | Exosome | Saliva | 19627513 |
| RLID:11000689 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
| RLID:11000690 | Exosome | Breast milk | 22211110 |
| RLID:11000691 | Exosome | Brain tissue | 23382797 |
| RLID:11000692 | Exosome | Plasma | 23663360 |
| RLID:11000693 | Exosome | Human mast cell line (HMC-1) | 24009880 |
| RLID:11000694 | Exosome | Cerebrospinal fluid | 25420022 |
| RLID:11000695 | Extracellular vesicle | HEK-293T cells | 22849433 |
| RLID:11000696 | Microvesicle | Seminal plasma | 23539611 |
| RLID:11000697 | Microvesicle | Follicular fluid | 23666971 |
| RLID-D:11000009 | Exosome | B lymphoblastoid cells|Chronic lymphocytic leukemia cells|Colon tissue|Endothelial cells|Epithelial cells|Lymphoma tissue|Mast cells|Tongue tissue | |
| RLID-D:11000269 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-17-5p | Diffuse large b cell lymphoma | MNDR-E-MI-19078 |
| MNDR | hsa-miR-17-5p | Splenic marginal zone lymphoma | MNDR-E-MI-19079 |
| MNDR | hsa-miR-17-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-19080 |
| MNDR | hsa-miR-17-5p | Oral squamous cell carcinoma | MNDR-E-MI-19081 |
| MNDR | hsa-miR-17-5p | Large cell neuroendocrine cancer | MNDR-E-MI-19082 |
| MNDR | hsa-miR-17-5p | Follicular cleaved lymphoma | MNDR-E-MI-19083 |
| MNDR | hsa-miR-17-5p | Medulloblastoma | MNDR-E-MI-19084 |
| MNDR | hsa-miR-17-5p | B cell lymphoma of malt type | MNDR-E-MI-19085 |
| MNDR | hsa-miR-17-5p | Small intestinal neuroendocrine tumor | MNDR-E-MI-19086 |
| MNDR | hsa-miR-17-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-19087 |
| MNDR | hsa-miR-17-5p | Ovarian clear cell carcinoma | MNDR-E-MI-19088 |
| MNDR | hsa-miR-17-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-19089 |
| MNDR | hsa-miR-17-5p | Autism spectrum disorder | MNDR-E-MI-19090 |
| MNDR | hsa-miR-17-5p | Lymphoma | MNDR-E-MI-19091 |
| MNDR | hsa-miR-17-5p | Lymphoma non-hodgkin | MNDR-E-MI-19092 |
| MNDR | hsa-miR-17-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-19093 |
| MNDR | hsa-miR-17-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-19094 |
| MNDR | hsa-miR-17-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-19095 |
| MNDR | hsa-miR-17-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-19096 |
| MNDR | hsa-miR-17-5p | Her2-receptor positive breast cancer | MNDR-E-MI-19097 |
| MNDR | hsa-miR-17-5p | Breast cancer luminal | MNDR-E-MI-19098 |
| MNDR | hsa-miR-17-5p | Lymphoblastic lymphoma | MNDR-E-MI-19099 |
| MNDR | hsa-miR-17-5p | Polycystic kidney diseases | MNDR-E-MI-19100 |
| MNDR | hsa-miR-17-5p | Thyroid carcinoma anaplastic | MNDR-E-MI-19101 |
| MNDR | hsa-miR-17-5p | Small intestine cancer | MNDR-E-MI-19102 |
| MNDR | hsa-miR-17-5p | Dermatomyositis | MNDR-E-MI-19103 |
| MNDR | hsa-miR-17-5p | Prostate cancer | MNDR-E-MI-19104 |
| MNDR | hsa-miR-17-5p | Gastric cancer | MNDR-E-MI-19105 |
| MNDR | hsa-miR-17-5p | Gastric lymphoma | MNDR-E-MI-19106 |
| MNDR | hsa-miR-17-5p | Alzheimer disease | MNDR-E-MI-19107 |
| MNDR | hsa-miR-17-5p | Intracranial aneurysm | MNDR-E-MI-19108 |
| MNDR | hsa-miR-17-5p | Bladder cancer | MNDR-E-MI-19109 |
| MNDR | hsa-miR-17-5p | Esophageal carcinoma | MNDR-E-MI-19110 |
| MNDR | hsa-miR-17-5p | Sarcoma | MNDR-E-MI-19111 |
| MNDR | hsa-miR-17-5p | Dysautonomia familial | MNDR-E-MI-19112 |
| MNDR | hsa-miR-17-5p | Primary biliary cirrhosis | MNDR-E-MI-19113 |
| MNDR | hsa-miR-17-5p | Leukemia | MNDR-E-MI-19114 |
| MNDR | hsa-miR-17-5p | Huntington disease | MNDR-E-MI-19115 |
| MNDR | hsa-miR-17-5p | Chorea | MNDR-E-MI-19116 |
| MNDR | hsa-miR-17-5p | Cardiovascular disease | MNDR-E-MI-19117 |
| MNDR | hsa-miR-17-5p | Carotid stenosis | MNDR-E-MI-19118 |
| MNDR | hsa-miR-17-5p | Lung cancer | MNDR-E-MI-19119 |
| MNDR | hsa-miR-17-5p | Down syndrome | MNDR-E-MI-19120 |
| MNDR | hsa-miR-17-5p | Parkinson disease | MNDR-E-MI-19121 |
| MNDR | hsa-miR-17-5p | Basal-like breast cancer | MNDR-E-MI-19122 |
| MNDR | hsa-miR-17-5p | Thyroid cancer | MNDR-E-MI-19123 |
| MNDR | hsa-miR-17-5p | Pituitary neoplasms | MNDR-E-MI-19124 |
| MNDR | hsa-miR-17-5p | Pancreatic cancer | MNDR-E-MI-19125 |
| MNDR | hsa-miR-17-5p | Malignant melanoma | MNDR-E-MI-19126 |
| MNDR | hsa-miR-17-5p | Lesch-nyhan syndrome | MNDR-E-MI-19127 |
| MNDR | hsa-miR-17-5p | Rectum adenocarcinoma | MNDR-E-MI-19128 |
| MNDR | hsa-miR-17-5p | Nephroblastoma | MNDR-E-MI-19129 |
| MNDR | hsa-miR-17-5p | Colon cancer | MNDR-E-MI-19130 |
| MNDR | hsa-miR-17-5p | Ischemic attack transient | MNDR-E-MI-19131 |
| MNDR | hsa-miR-17-5p | Colon adenocarcinoma | MNDR-E-MI-19132 |
| MNDR | hsa-miR-17-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-19133 |
| MNDR | hsa-miR-17-5p | Familial ovarian cancer | MNDR-E-MI-19134 |
| MNDR | hsa-miR-17-5p | Acromegaly | MNDR-E-MI-19135 |
| MNDR | hsa-miR-17-5p | Prostate adenocarcinoma | MNDR-E-MI-19136 |
| MNDR | hsa-miR-17-5p | Kidney cancer | MNDR-E-MI-19137 |
| MNDR | hsa-miR-17-5p | Carcinoma ductal breast | MNDR-E-MI-19138 |
| MNDR | hsa-miR-17-5p | Invasive ductal carcinoma | MNDR-E-MI-19139 |
| MNDR | hsa-miR-17-5p | Glioblastoma | MNDR-E-MI-19140 |
| MNDR | hsa-miR-17-5p | Glioma | MNDR-E-MI-19141 |
| MNDR | hsa-miR-17-5p | Oligodendroglioma | MNDR-E-MI-19142 |
| MNDR | hsa-miR-17-5p | Central nervous system lymphoma | MNDR-E-MI-19143 |
| MNDR | hsa-miR-17-5p | Chordoma | MNDR-E-MI-19144 |
| MNDR | hsa-miR-17-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-19145 |
| MNDR | hsa-miR-17-5p | Epilepsy temporal lobe | MNDR-E-MI-19146 |
| MNDR | hsa-miR-17-5p | Osteosarcoma | MNDR-E-MI-19147 |
| MNDR | hsa-miR-17-5p | Liposarcoma | MNDR-E-MI-19148 |
| MNDR | hsa-miR-17-5p | Coronary artery disease | MNDR-E-MI-19149 |
| MNDR | hsa-miR-17-5p | Pancreatic ductal adenocarcinoma | MNDR-E-MI-19150 |
| MNDR | hsa-miR-17-5p | Middle cerebral artery infarction | MNDR-E-MI-19151 |
| MNDR | hsa-miR-17-5p | Meningioma | MNDR-E-MI-19152 |
| MNDR | hsa-miR-17-5p | Liver cancer | MNDR-E-MI-19153 |
| MNDR | hsa-miR-17-5p | Gastric adenocarcinoma | MNDR-E-MI-19154 |
| MNDR | hsa-miR-17-5p | Cervical squamous cell carcinoma | MNDR-E-MI-19155 |
| MNDR | hsa-miR-17-5p | Pituitary adenoma | MNDR-E-MI-19156 |
| MNDR | hsa-miR-17-5p | Lung squamous cell carcinoma | MNDR-E-MI-19157 |
| MNDR | hsa-miR-17-5p | Carcinoma lung non-small-cell | MNDR-E-MI-19158 |
| MNDR | hsa-miR-17-5p | Lung adenocarcinoma | MNDR-E-MI-19159 |
| MNDR | hsa-miR-17-5p | Adrenocortical carcinoma | MNDR-E-MI-19160 |
| MNDR | hsa-miR-17-5p | Thyroid carcinoma | MNDR-E-MI-19161 |
| MNDR | hsa-miR-17-5p | Ovarian carcinoma | MNDR-E-MI-19162 |
| MNDR | hsa-miR-17-5p | Bladder urothelial carcinoma | MNDR-E-MI-19163 |
| MNDR | hsa-miR-17-5p | Pancreatic adenocarcinoma | MNDR-E-MI-19164 |
| MNDR | hsa-miR-17-5p | Cervical cancer | MNDR-E-MI-19165 |
| MNDR | hsa-miR-17-5p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-19166 |
| MNDR | hsa-miR-17-5p | Kidney renal clear cell carcinoma | MNDR-E-MI-19167 |
| MNDR | hsa-miR-17-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-19168 |
| MNDR | hsa-miR-17-5p | Clear cell renal cell carcinoma | MNDR-E-MI-19169 |
| MNDR | hsa-miR-17-5p | Biliary tract cancer | MNDR-E-MI-19170 |
| MNDR | hsa-miR-17-5p | Pituitary carcinoma | MNDR-E-MI-19171 |
| MNDR | hsa-miR-17-5p | Cholangiocarcinoma | MNDR-E-MI-19172 |
| MNDR | hsa-miR-17-5p | Esophageal cancer | MNDR-E-MI-19173 |
| MNDR | hsa-miR-17-5p | Liver cirrhosis | MNDR-E-MI-19174 |
| MNDR | hsa-miR-17-5p | Prolactinoma | MNDR-E-MI-19175 |
| MNDR | hsa-miR-17-5p | Lung small cell carcinoma | MNDR-E-MI-19176 |
| MNDR | hsa-miR-17-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-19177 |
| MNDR | hsa-miR-17-5p | Kidney diseases | MNDR-E-MI-19178 |
| MNDR | hsa-miR-17-5p | T acute lymphoblastic leukemia | MNDR-E-MI-19179 |
| MNDR | hsa-miR-17-5p | Acute t cell leukemia | MNDR-E-MI-19180 |
| MNDR | hsa-miR-17-5p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-19181 |
| MNDR | hsa-miR-17-5p | Fibromyalgia | MNDR-E-MI-19182 |
| MNDR | hsa-miR-17-5p | Pulmonary hypertension | MNDR-E-MI-19183 |
| MNDR | hsa-miR-17-5p | Adenoma | MNDR-E-MI-19184 |
| MNDR | hsa-miR-17-5p | Breast invasive carcinoma | MNDR-E-MI-19185 |
| MNDR | hsa-miR-17-5p | Hepatocellular carcinoma | MNDR-E-MI-19186 |
| MNDR | hsa-miR-17-5p | Familiar ovarian carcinoma | MNDR-E-MI-19187 |
| MNDR | hsa-miR-17-5p | B-cell lymphoma | MNDR-E-MI-19188 |
| MNDR | hsa-miR-17-5p | Rheumatoid arthritis | MNDR-E-MI-19189 |
| MNDR | hsa-miR-17-5p | T-cell leukemia | MNDR-E-MI-19190 |
| MNDR | hsa-miR-17-5p | Retinoblastoma | MNDR-E-MI-19191 |
| MNDR | hsa-miR-17-5p | Neuroblastoma | MNDR-E-MI-19192 |
| MNDR | hsa-miR-17-5p | Chronic fatigue syndrome | MNDR-E-MI-19193 |
| MNDR | hsa-miR-17-5p | Chronic myeloid leukemia | MNDR-E-MI-19194 |
| MNDR | hsa-miR-17-5p | Hodgkin lymphoma | MNDR-E-MI-19195 |
| MNDR | hsa-miR-17-5p | Burkitt lymphoma | MNDR-E-MI-19196 |
| MNDR | hsa-miR-17-5p | Lymphosarcoma | MNDR-E-MI-19197 |
| MNDR | hsa-miR-17-5p | Tonsil cancer | MNDR-E-MI-19198 |
| MNDR | hsa-miR-17-5p | Psoriasis | MNDR-E-MI-19199 |
| MNDR | hsa-miR-17-5p | Acute myelocytic leukemia | MNDR-E-MI-19200 |
| MNDR | hsa-miR-17-5p | Colorectal cancer | MNDR-E-MI-19201 |
| MNDR | hsa-miR-17-5p | Nasopharyngeal carcinoma | MNDR-E-MI-19202 |
| MNDR | hsa-miR-17-5p | Type 2 diabetes mellitus | MNDR-E-MI-19203 |
| MNDR | hsa-miR-17-5p | Multiple myeloma | MNDR-E-MI-19204 |
| MNDR | hsa-miR-17-5p | Uterine cervical neoplasms | MNDR-E-MI-19205 |
| MNDR | hsa-miR-17-5p | Ependymoma | MNDR-E-MI-19206 |
| MNDR | hsa-miR-17-5p | Nasopharyngeal cancer | MNDR-E-MI-19207 |
| MNDR | hsa-miR-17-5p | Prostatic neoplasms | MNDR-E-MI-19208 |
| MNDR | hsa-miR-17-5p | Arsenic poisoning | MNDR-E-MI-19209 |
| MNDR | hsa-miR-17-5p | Stroke lacunar | MNDR-E-MI-19210 |
| MNDR | hsa-miR-17-5p | Non-alcoholic fatty liver disease | MNDR-E-MI-19211 |
| MNDR | hsa-miR-17-5p | Breast cancer her3+ negative | MNDR-E-MI-19212 |
| MNDR | hsa-miR-17-5p | Duke A | MNDR-E-MI-19213 |
| MNDR | hsa-miR-17-5p | Tubulovillous adenoma | MNDR-E-MI-19214 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | ABCA1 | Homo sapiens | RR00022096 |
TOP